Tharimmune, INC. (CNTN) — 10-Q Filings

10-Q Filings (6)

• Tharimmune Narrows Q3 Loss, Shifts TH104 Focus to Opioid Prophylaxis — Nov 12, 2025 Risk: high
  Tharimmune, Inc. (THAR) reported a net loss of $2.10 million for the three months ended September 30, 2025, a significant improvement from the $3.80 million net
• Tharimmune, Inc. Files 10-Q for Q2 2025 — Aug 14, 2025 Risk: medium
  Tharimmune, Inc. filed its 10-Q for the period ending June 30, 2025. The company, formerly known as Hillstream BioPharma Inc., is focused on pharmaceutical prep
• Tharimmune, Inc. Files Q1 2025 10-Q — May 12, 2025 Risk: medium
  Tharimmune, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Hillstream BioPharma Inc., is in the pharmaceutical prepara
• Tharimmune, Inc. Files Q3 2024 10-Q Report — Nov 7, 2024 Risk: medium
  Tharimmune, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Hillstream BioPharma Inc., is focused on pharmaceutical
• Tharimmune, Inc. Files Q2 2024 10-Q — Aug 9, 2024 Risk: medium
  Tharimmune, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Hillstream BioPharma Inc., is in the pharmaceutical preparat
• Tharimmune, Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  Tharimmune, Inc. (CNTN) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Tharimmune, Inc. filed a 10-Q report for the quarterly period ended March 3

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX